Abstract: A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.

Abstract: Described are methods and compositions for processes of preparing a radioactive solution of Sn-117m tetraiodide. Aspects include reacting a radioactive solid Sn containing Sn-117m with a solution of I2 in an organic solvent at a temperature and for a duration sufficient to result in the formation of Sn-117m tetraiodide. Then, the organic solvent is removed by evaporation to leave dry Sn-117m tetraiodide. The organic solvent is a low boiling point solvent capable of dissolving I2 and Sn tetraiodide. The organic solvent is selected from the group consisting of an alcohol and a chlorinated solvent. In embodiments may be selected from the group consisting of dichloromethane, trichloromethane, tetrachloromethane, or mixtures thereof. In embodiments, the organic solvent excludes alcohol. The I2 may be in a slight molar excess to the radioactive solid Sn. The method may further include distilling the reactants to remove excess I2 from the distillate.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.

Abstract: Described are methods and compositions for processes of preparing a radioactive solution of Sn-117m tetraiodide. Aspects include reacting a radioactive solid Sn containing Sn-117m with a solution of I2 in an organic solvent at a temperature and for a duration sufficient to result in the formation of Sn-117m tetraiodide. Then, the organic solvent is removed by evaporation to leave dry Sn-117m tetraiodide. The organic solvent is a low boiling point solvent capable of dissolving I2 and Sn tetraiodide. The organic solvent is selected from the group consisting of an alcohol and a chlorinated solvent. In embodiments may be selected from the group consisting of dichloromethane, trichloromethane, tetrachloromethane, or mixtures thereof. In embodiments, the organic solvent excludes alcohol. The I2 may be in a slight molar excess to the radioactive solid Sn. The method may further include distilling the reactants to remove excess I2 from the distillate.

Abstract: Low dose radiation, including conversion electron energy induces apoptosis in peripheral macrophages and CNS microglia. The transport of Sn-117m, a conversion electron emitter has been shown to be deliverable into the CNS across the blood-brain-barrier (BBB). The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor member of the immunoglobulin super family which is able to bind A13 peptide and 13-sheet fibrils. It is expressed in endothelial cells, smooth muscle cells, microglia and neurons, and is implicated in the transport of A13 through the BBB, oxidative stress-mediated neurotoxicity, and adverse microglia inflammatory responses. The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Enhanced levels of RAGE ligands in Alzheimer's disease are thought to contribute to the cause of this disorder.

Abstract: A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.

Abstract: A targeted radiopharmaceutical of chemical Formula I, below, is disclosed wherein Q+3 is a trivalent radioactive isotope ion; M is a proton (H+), an ammonium ion or an alkali metal ion; “g” is a number that is 1 to about 12; the boxed mAb MNPR-101 represents the chemically-bonded humanized mAb MNPR-101; and Y? is an optional anion present in an amount needed to balance the ionic charge. A pharmaceutical composition that comprises a theranostic effective amount of a Formula I targeted radiopharmaceutical dissolved or dispersed in a pharmaceutically acceptable diluent is also disclosed, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis. A targeted pro-radiopharmaceutical construct similar to that of Formula I but without the radioisotope (Formula III) is also contemplated.

Abstract: A targeted radiopharmaceutical comprising a targeting species chemically-bonded to a PCTA-chelated Q+3 trivalent radioactive ion of Formula I is disclosed. Six of R1 through R7 are H and the seventh is a reacted functionality, Z, that forms the chemical bond with the targeting species, T. “g” is a number whose average value is 1 to about 12. X1, X2, and X3, are substituent groups that can coordinate to the Q+3 ion and/or help neutralize the ionic charge. Anion Y? is optionally present to balance the ionic charge. A pharmaceutical composition comprising a theranostic effective amount of a targeted radiopharmaceutical of Formula I in a pharmaceutically acceptable diluent is also contemplated, as are a method for treating and/or diagnosing a mammalian host having a disease, disorder or condition characterized by undesired angiogenesis, tumor growth and/or tumor metastasis.

Abstract: A composition comprising including a homogeneous tin-117m colloid comprising tin-117m, and an ascorbic acid is provided, the composition naturally has a white coloration. The composition is visually distinct from a conventional homogeneous tin-117m colloid because conventional colloids have an orange-yellow color. The addition of ascorbic acid changes the color of the composition without adding toxicity and without changing the therapeutic effects of the homogeneous tin-117m colloid. A use and a method of making the same is also provided.

Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.

Abstract: A polymeric radiation-source with customized geometries to maximize receipt of radiation into treatment areas that is formed from either radioisotopes molecularly bonded to a polymer or radioisotopes encased within a polymer.

Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.

Abstract: Tin(IV)-117m is reduced by an acidic antimony solution to tin(II)-117m. A chelant is added to the solution of tin(II)-117m, and the pH is raised, forming tin(II)-117m chelant complex. The chelant is a bifunctional chelant, preferably attached to a bioactive molecule and reacted with the tin(II)-117m to form a radiopharmaceutical.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.

Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Abstract: Described are methods and compositions for processes of preparing a radioactive solution of Sn-117m tetraiodide. Aspects include reacting a radioactive solid Sn containing Sn-117m with a solution of I2 in an organic solvent at a temperature and for a duration sufficient to result in the formation of Sn-117m tetraiodide. Then, the organic solvent is removed by evaporation to leave dry Sn-117m tetraiodide. The organic solvent is a low boiling point solvent capable of dissolving I2 and Sn tetraiodide. The organic solvent is selected from the group consisting of an alcohol and a chlorinated solvent. In embodiments may be selected from the group consisting of dichloromethane, trichloromethane, tetrachloromethane, or mixtures thereof. In embodiments, the organic solvent excludes alcohol. The I2 may be in a slight molar excess to the radioactive solid Sn. The method may further include distilling the reactants to remove excess I2 from the distillate.

Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.

Abstract: This invention relates to a solid veterinary formulation and a method for its oral administration to an animal, especially cats or dogs, to remove fluid overload in the animal by using a mixture of a water-absorbing polymer and solid fat, optionally having one or more supplemental ingredients. The fluid overload is caused by congestive heart failure or renal disease. The polymer is capable of absorbing at least 10 times its weight in physiological saline. The polymer and other waste materials are excreted in the feces.

Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.

Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.